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Survival Implication of Left Ventricular End-Systolic
Diameter in Mitral Regurgitation Due to Flail Leaflets
A Long-Term Follow-Up Multicenter Study
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Objectives This study analyzed the association of left ventricular end-systolic diameter (LVESD) with survival after diagnosis
in organic mitral regurgitation (MR) due to flail leaflets.
Background LVESD is a marker of left ventricular function in patients with organic MR but its association to survival after
diagnosis is unknown.
Methods The MIDA (Mitral Regurgitation International Database) registry is a multicenter registry of echocardiographically
diagnosed organic MR due to flail leaflets. We enrolled 739 patients with MR due to flail leaflets (age 65  12
years; ejection fraction: 65  10%) in whom LVESD was measured (36  7 mm).
Results Under conservative management, 10-year survival and survival free of cardiac death were higher with LVESD
40 mm versus 40 mm (64  5% vs. 48  10%; p  0.001, and 73  5% vs. 63  10%; p  0.001). LVESD
40 mm independently predicted overall mortality (hazard ratio [HR]: 1.95, 95% confidence interval [CI]: 1.01
to 3.83) and cardiac mortality (HR: 3.09, 95% CI: 1.35 to 7.09) under conservative management. Mortality risk
increased linearly with LVESD 40 mm (HR: 1.15, 95% CI: 1.04 to 1.27 per 1-mm increment). During the entire
follow-up (including post-surgical), LVESD 40 mm independently predicted overall mortality (HR: 1.86, 95% CI:
1.24 to 2.80) and cardiac mortality (HR: 2.14, 95% CI: 1.29 to 3.56), due to persistence of excess mortality in
patients with LVESD 40 mm after surgery (HR: 1.86, 95% CI: 1.11 to 3.15 for overall death, and HR: 1.81,
95% CI: 1.05 to 3.54 for cardiac death).
Conclusions In MR due to flail leaflets, LVESD 40 mm is independently associated with increased mortality under medical man-
agement but also after mitral surgery. These findings support prompt surgical rescue in patients with LVESD 40
mm but also suggest that best preservation of survival is achieved in patients operated before LVESD reaches 40
mm. (J Am Coll Cardiol 2009;54:1961–8) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.047h
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nn Western countries, degenerative valve disease is the most
requent cause of organic mitral regurgitation (MR) (1,2).
evere organic MR is a progressive disease associated with
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ccepted June 9, 2009.igh morbidity and excess mortality under medical manage-
ent (3–6). Mitral valve surgery is required for patients
ith severe MR and overt symptoms because these patients
ncur high mortality. However, symptoms are not sensitive
or patients at high risk, and patients who undergo surgery
or symptoms continue to incur high mortality even after
See page 1969
uccessful surgery. Thus, there has been an ongoing search
or markers of risk under medical management that would
e more sensitive and incremental to symptoms and would
ot imply excess risk after surgery. Whereas left ventricular
LV) dysfunction (3,7–9) is considered useful for that
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proach in patients with severe
MR is still a subject of debate
(6,10,11).
In that regard, reduced preop-
erative LV ejection fraction (EF)
is a predictor of mortality and
post-operative LV dysfunction in
patients with chronic MR (12–15)
and is now included as a class I
indication for surgery in guide-
ines (7,8). Conversely, whereas left ventricular end-systolic
iameter (LVESD) is also included as an indication for
urgery in guidelines, data on the prognostic importance of
VESD are scarce (7,15–20). To our knowledge, there are
o data on the impact of LVESD on long-term survival
fter diagnosis in patients with severe organic MR. This
robably explains the discordance between European and
merican guidelines with regard to the LVESD cut-off
sed for the timing of mitral valve repair, especially in
symptomatic patients with severe MR (7,8).
The MIDA (Mitral Regurgitation International Data-
ase) registry was set up specifically as a multicenter study of
he medical and surgical outcome of MR in routine practice.
e identified retrospectively consecutive patients with
chocardiographically diagnosed flail leaflet (4), a diagnosis
sually associated with severe MR (8,21). The aims of the
resent analysis were to study the association of LVESD
ith survival after diagnosis and to analyze whether this
ssociation applied to follow-up under conservative man-
gement and after surgical correction of MR.
ethods
tudy design. The MIDA registry was assembled by sys-
ematically merging the consecutive experience with MR
ue to flail leaflets of 5 centers: 4 tertiary centers in Europe
University Hospitals in Amiens and Marseille, France, and
ologna and Modena, Italy), and 1 center in the U.S.
Mayo Clinic, Rochester, Minnesota). Preliminary data
rom the European registry have been previously published
4). The process of forming each center’s dataset involved
etrospective identification of consecutive patients diag-
osed with MR due to flail leaflet since inception of the
chocardiographic database. Echocardiographic variables
ere obtained by download of standardized measurements,
rospectively entered in the databases (4). We obtained
nstitutional review board authorizations before conducting
he study. The study was conducted in accordance with
nstitutional policies, national legal requirements, and the
evised Helsinki declaration.
Patients were screened for the study if they had degen-
rative MR with flail leaflet diagnosed by 2-dimensional
chocardiography between 1980 and 2004. Specific eligibil-
ty criteria (4) were: 1) presence of echocardiographically
Abbreviations
and Acronyms
AF  atrial fibrillation
EF  ejection fraction
LV  left ventricle/left
ventricular
MR  mitral regurgitation
LVESD  left ventricular
end-systolic diameteriagnosed flail leaflet; 2) availability of a comprehensive llinical/instrumental evaluation at the time of baseline echo-
ardiography; 3) exclusion of ischemic MR; and 4) absence
f significant concomitant aortic valve disease, congenital
iseases, mitral stenosis, and previous valve surgery. Patients
ere excluded if they denied authorization for research
articipation. A comorbidity index summating the patient’s
ndividual comorbidities was calculated (22) and atrial
brillation (AF) at baseline was determined by electro-
ardiogram. A total of 861 patients were enrolled in the
egistry. For the present analysis, we considered only
atients in whom a measurement of LVESD was avail-
ble (n  739).
chocardiography. Transthoracic echocardiograms were
erformed within routine clinical practice, using standard
ethods (4). Left ventricular dimensions were assessed
rom parasternal long-axis views by 2-dimensional guided
-mode using the leading edge methodology at end dias-
ole and end systole. Severity of MR was assessed semiquan-
itatively on a scale from 1 to 4 by Doppler echocardiogra-
hy (4). Diagnosis of flail leaflet was based on the failure of
eaflet cooptation, with rapid systolic movement of the
nvolved leaflet tip in the left atrium (3,4). Echocardiograms
ere used as collected at the time of the index echocardi-
graphy, without subsequent modification.
ollow-up. Follow-up collection was complete in each
enter for 95% of enrolled patients. The main end point
as survival after diagnosis starting at baseline echocardio-
raphic evaluation and reaching up to last follow-up under
edical management (censored at surgery). Other end
oints were cardiac mortality, overall survival encompassing
edical and surgical management and post-operative sur-
ival in patients who underwent surgery. During follow-up,
atients were monitored by their personal physicians.
vents were ascertained by clinical interviews and/or by
elephone calls to physicians, patients, and (if necessary)
ext of kin. Autopsy records and death certificates were
onsulted for attribution of causes of death.
tatistical analysis. Continuous variables were expressed
s mean  1 SD and compared with Student t tests.
ategorical variables were summarized as frequency per-
entages and analyzed by chi-square tests. For the analysis
f outcome under conservative treatment, data were cen-
ored at the time of cardiac surgery, if performed. The entire
ollow-up was used to analyze outcomes under conservative
nd surgical treatment. Event rates  1 SE were estimated
ccording to the Kaplan-Meier method and compared using
2-sided log-rank test. Univariate and multivariable anal-
ses of time to events were performed using Cox propor-
ional hazards models with LVESD as an independent
ariable in continuous and categorical format: cut-off value
f 40 mm based on U.S. recommendations (7). For multi-
ariable analyses of mortality we used predefined Cox
roportional hazards multivariable models that included
ovariates considered of potential prognostic impact (age,
ex, comorbidity index, symptoms at baseline, AF at base-
ine, and EF). We also conducted analyses stratified by
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November 17, 2009:1961–8 LV Size in Mitral Regurgitationresence or absence of baseline characteristics representing
urrent class I indications for surgery (symptoms or EF
60%) with measurement of statistical interaction between
hose characteristics and LVESD in predicting mortality.
he proportional hazards assumption was confirmed using
tatistics and graphs based on the Schoenfeld residuals. For
ontinuous variables, the assumption of linearity was as-
essed by plotting residuals against independent variables.
e used penalized smoothing splines (P-splines) to illus-
rate the association of LVESD as a continuous variable and
he risk of overall mortality (23). The effect of surgery on the
utcome was analyzed as a time-dependent covariate in a
ox multivariable model with the use of data from the
ntire follow-up. A significance level of 0.05 was assumed
or all statistical tests. All p values are results of 2-tailed
ests. Data were analyzed with SPSS version 13.0 (SPSS
nc., Chicago, Illinois) and S-Plus version 8.0 (Insightful
nc., Seattle, Washington).
aseline Characteristics of the 739 Patients With Organic Mitral RTable 1 Baseline Characteristics of the 739 Patients With Org
All Patients
(n  739)
Characteristics
Age, yrs 64.8  11.9
Male sex 69.7 (515)
NYHA functional class
I 39.6 (293)
II 29.5 (218)
III 22.7 (168)
IV 8.0 (59)
Cardiac history and risk factors
Coronary artery disease 8.1 (60)
Hypertension 34.5 (255)
Diabetes mellitus 0.9 (7)
Smoking 34.5 (255)
Dyslipidemia 30.2 (223)
Infective endocarditis 10.6 (78)
Charlson comorbidity index 1.05  1.19
Atrial fibrillation 20.7 (153)
Echocardiographic data
Flail
Posterior leaflet 81.9 (605)
Anterior leaflet 6.8 (50)
Both leaflets 10.9 (81)
Nonspecified 0.4 (3)
Left ventricular end-diastolic diameter, mm 59.6  7.9
Left ventricular end-systolic diameter, mm 35.8  7.1
Ejection fraction, % 65.3  10.3
Left atrial diameter,* mm 50.1  8.9
Systolic pulmonary artery pressure,† mm Hg 43.2  15.2
Medical therapy
Angiotensin-converting enzyme inhibitors 48.0 (355)
Beta-blockers 17.5 (129)
Diuretics 43.4 (320)
Warfarin 29.0 (214)
Antiplatelet agents 24.6 (182)alues are mean  SD or % (n). *Data available for 690 patients (93.4%). †Data available in 422 patien
LVESD  left ventricular end-systolic diameter; NYHA  New York Heart Association.esults
aseline characteristics and management. The baseline
haracteristics of the 739 patients with organic MR overall
nd according to LVESD are presented in Table 1. Ninety-
ve percent of patients had grade 3 to 4 MR by Doppler
chocardiography. Flail leaflet was attributable to a degen-
rative process in 661 patients (89%) and to infective
ndocarditis in the remaining 78 (11%). Eight percent of
atients (n  60) had a history of clinical coronary artery
isease. Of the total patients, 293 (40%) were in New York
eart Association functional class I and EF was 60% in
91 patients (80%).
The mean LVESD was 35.8  7.14 mm (median 36
m; interquartile range 31 to 40 mm). In 545 patients
73.7%), LVESD was 40 and 40 mm in the remaining
94 patients (26.3%). Patients with larger LVESD were
ostly men, had more severe symptoms and a higher
gitation Due to Flail Leaflets According to LVESDMitral Regurgitation Due to Flail Leaflets According to LVESD
LVESD <40 mm
(n  545)
LVESD >40 mm
(n  194) p Value
65.3  11.5 63.5  12.7 0.07
63.9 (348) 86.1 (167) 0.001
41.9 (228) 33.5 (65) 0.16
28.1 (153) 33.5 (65)
21.7 (118) 25.8 (50)
8.3 (45) 7.2 (14)
7.3 (40) 10.3 (20) 0.19
36.2 (197) 29.9 (58) 0.11
0.9 (5) 1.0 (2) 0.89
32.3 (176) 40.9 (79) 0.03
31.4 (169) 28.1 (54) 0.39
10.5 (57) 10.8 (21) 0.89
1.04  1.17 1.1  1.2 0.54
17.4 (95) 29.9 (58) 0.001
83.3 (454) 77.8 (151) 0.23
6.2 (34) 8.2 (16)
10.1 (55) 13.4 (26)
0.3 (2) 0.5 (1)
56.9  6.3 67.1  6.9 0.001
32.7  4.6 44.8  5.3 0.001
68.6  7.2 57.1  9.9 0.001
48.5  7.8 54.9  10.2 0.001
43.3  15.9 42.9  13.5 0.85
48.9 (266) 46.8 (89) 0.63
17.8 (97) 16.8 (32) 0.77
40.6 (221) 52.1 (99) 0.006
24.8 (135) 41.6 (79) 0.001
24.3 (132) 26.3 (50) 0.57eguranicts (57.1%).
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LV Size in Mitral Regurgitation November 17, 2009:1961–8requency of AF, but no difference in comorbidity index
Table 1).
Management was solely conservative in 187 patients
25.3%) and was medical followed by surgery in 552 patients
74.7%). Mean duration of follow-up with conservative
reatment was 2.2  3.1 years. Mean overall duration of
ollow-up was 6.1  3.7 years.
utcome in conservatively managed patients. In patients
anaged conservatively, 74 deaths were recorded. Overall
urvival rates of 1, 5, and 10 years were 97  1%, 80  3%,
nd 58  5%, respectively. The 10-year survival rate was
igher for patients with LVESD 40 mm than for patients
Figure 1 Overall Survival According to
LVESD in Patients With Organic MR
Overall survival according to left ventricular end-systolic diameter (LVESD) in
patients with organic mitral regurgitation (MR): (A) conservative management
(B) medical and surgical treatment.
elative Risk of Overall Death and Death From Cardiac Causes Assith Organic Mitral Regurgi ation Due o lail Le flets: Results ofTable 2 Relati Risk of Overall Death and Death From CardiacWith Organic Mitral Regurgitation Due to Flail Leaflets
Medical Ma
HR (95% CI)
LVESD 40 mm
Overall death
Adjusted for age, sex, and comorbidity 2.15 (1.26–3.66
Adjusted for age, sex, comorbidity, symptoms, EF, and AF 1.95 (1.01–3.83
Death from cardiac causes
Adjusted for age, sex, and comorbidity 2.87 (1.49–5.52
Adjusted for age, sex, comorbidity, symptoms, EF, and AF 3.09 (1.35–7.09
Per 1-mm increment in LVESD
Overall death
Adjusted for age, sex, and comorbidity 1.08 (1.04–1.12
Adjusted for age, sex, comorbidity, symptoms, EF, and AF 1.07 (1.02–1.13
Death from cardiac causes
Adjusted for age, sex and comorbidity 1.11 (1.06–1.15
Adjusted for age, sex, comorbidity, symptoms, EF, and AF 1.13 (1.06–1.20
Analyses of outcome under medical management and post-operative outcome included age, se
Analysis of outcome with medical and surgical treatment included the previously mentioned covariates
AF  atrial fibrillation; CI  confidence interval; EF  ejection fraction; HR  hazard ratio; other abbreith LVESD 40 mm (Fig. 1A). Older age, higher New
ork Heart Association functional class, coronary artery
isease, comorbidity index, AF at baseline, EF, and diuretic
se were also univariate predictors of mortality (all p 
.03). End-diastolic LV diameter was not associated with
ncreased mortality (p  0.16).
After adjustment for age, sex, and comorbidity, LVESD
as independently associated with mortality (adjusted haz-
rd ratio [HR]: 2.15, 95% confidence interval [CI]: 1.26 to
.66 for LVESD 40 mm vs. LVESD 40 mm, and HR:
.08, 95% CI: 1.04 to 1.12 per 1-mm increment in
VESD) (Table 2). Further adjustment for symptoms, AF
nd EF did not influence these independent relationships
Table 2). To estimate the character of the relationship
etween LVESD and the risk of overall mortality under
onservative management, we used spline functions for
VESD (Fig. 2). In multivariable analysis, there was no
ncrease in mortality risk with increasing LVESD when it
emained 40 mm (adjusted HR: 1.03, 95% CI: 0.95 to
.10 per 1-mm LVESD increment, p  0.48). With
VESD 40 mm, there was a steep increase in mortality
isk with increasing LVESD (adjusted HR: 1.15, 95% CI:
.04 to 1.27 per 1-mm LVESD increment, p  0.007).
ompared with patients with LVESD40 mm, those with
VESD between 40 and 45 mm (adjusted HR: 1.89, 95%
I: 0.98 to 3.4, p  0.058), as well as those with LVESD
45 mm (adjusted HR: 3.7, 95% CI: 1.7 to 7.3, p 0.002)
isplayed excess mortality under medical management. In
he subgroup with symptoms or EF 60% at baseline (n 
20), the mean follow-up under medical management was
.2 2.1 years and the delay between diagnosis and surgery
as explained by improvement in symptoms under medical
anagement. The risk related to LVESD was identical in
hese patients with potential “guideline surgical indication
ed With LVESD in Patientsnivariate and Multivariable Analysesses Associated Wi h LVESD in Pati nts
ults of Cox Univariate and Multivariable Analyses
ent*
Medical and Surgical
Management† Post-Operative Outcome*
p Value HR (95% CI) p Value HR (95% CI) p Value
0.005 2.01 (1.42–2.83) 0.001 1.99 (1.26–3.14) 0.003
0.045 1.86 (1.24–2.80) 0.003 1.86 (1.11–3.15) 0.019
0.002 2.33 (1.52–3.58) 0.001 2.21 (1.24–3.96) 0.007
0.008 2.14 (1.29–3.56) 0.003 1.81 (1.05–3.54) 0.04
0.001 1.05 (1.03–1.08) 0.001 1.04 (1.01–1.06) 0.006
0.005 1.04 (1.02–1.07) 0.001 1.03 (1.01–1.07) 0.04
0.001 1.08 (1.05–1.10) 0.001 1.06 (1.03–1.09) 0.001
0.001 1.07 (1.04–1.11) 0.001 1.05 (1.01–1.10) 0.01
son comorbidity index, presence of symptoms at baseline, AF at baseline, and EF as covariates.ociatCox UCau
: Res
nagem
)
)
)
)
)
)
)
)
x, Charl
and surgery as a time-dependent covariate.
viations as in Table 1.
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November 17, 2009:1961–8 LV Size in Mitral Regurgitationt baseline” (adjusted HR: 1.07, 95% CI: 1.01 to 1.11 per
-mm LVESD increment, p  0.02) and in those with
either symptoms nor lowered EF (adjusted HR: 1.07,
5% CI: 1.004 to 1.14 per 1-mm LVESD increment,
 0.035). There was no interaction between presence
f symptoms or EF 60% and the effect of LVESD on
urvival (p  0.69).
In patients in whom body surface area was available (n 
55), an LVESD 22 mm/m2 was associated with excess
ortality under medical management (adjusted HR: 2.03,
5% CI: 1.06 to 3.89, p  0.03). There was an increase in
ortality risk with increasing LVESD when LVESD was
22 mm/m2 (adjusted HR: 1.12, 95% CI: 1.01 to 1.23 per
-mm LVESD increment, p  0.01), but not when it
emained 22 mm/m2 (p  0.62). The model with unad-
usted LVESD was slightly but significantly superior to that
ith LVESD normalized (p  0.045) so that the unad-
usted value was used as the main independent variable in
ur analysis.
The relationship between LVESD 40 mm and mortal-
ty under medical management was unchanged after exclud-
ng patients with moderate MR (adjusted HR: 2.09, 95%
I: 1.03 to 4.26, p  0.04) or patients with history of
nfective endocarditis (adjusted HR: 1.88, 95% CI: 1.01 to
.95, p  0.044).
During conservative follow-up, 49 deaths of cardiac
auses occurred. Causes of death were LV dysfunction (n 
1, 64%), unexplained sudden death (n  14, 28%),
hromboembolism (n  2, 4%), myocardial infarction (n 
, 2%), and infective endocarditis (n  1, 2%). Cardiac
ortality rates for 1, 5, and 10 years were 2  0.7%, 13 
%, and 29  5%, respectively, for the entire cohort. The
0-year cardiac mortality rate was significantly lower for
atients with LVESD 40 mm (Fig. 3A). In multivariable
nalysis, a greater LVESD was independently predictive of
eath from cardiac causes (Table 2). There was a significant
Figure 2 Association Between LVESD and the Risk
of Overall Mortality Under Conservative Management
Hazard ratio (solid line) and 95% confidence intervals were estimated in a Cox
multivariable model with left ventricular end-systolic diameter (LVESD) repre-
sented as a spline function.ncrease in cardiac mortality with increasing LVESD whent was 40 mm (HR: 1.16, 95% CI: 1.05 to 1.28 per 1-mm
VESD increment, p  0.004), but not when it remained
40 mm (p  0.20).
utcome with medical and surgical treatment. Mitral
alve surgery was eventually performed in 552 patients
75%) on the basis of the following indications: dyspnea/
ongestive heart failure in 371 patients (67%), patient
nd/or physician preference in 111 (20%), LV dilation in 17
3%), infective endocarditis in 18 (3%), AF in 1 (0.2%), and
iscellaneous reasons in the remaining 34 patients (6%).
he mitral valve was repaired in 78% of patients and
eplaced in 22%. In 86 patients (15.6%), a coronary artery
ypass graft was also performed during mitral valve surgery.
he rate of cardiac surgery was 3.6  0.7%, 32.8  1.8%,
nd 74.0  1.9% at 1, 5, and 10 years, respectively, after
iagnosis.
During follow-up with medical and surgical treatment,
62 deaths were recorded. Overall survival rates for 1, 5, and
0 years were 97  0.6%, 85  1.4%, and 69  2%,
espectively. The 10-year survival rate was higher for pa-
ients with LVESD 40 mm than for patients with
VESD 40 mm (Fig. 1B). Older age, higher New York
eart Association functional class, coronary artery disease,
istory of infective endocarditis, comorbidity index, AF at
aseline, EF, and diuretic use were also univariate predictors
f overall mortality (all p  0.03). End-diastolic LV
iameter was not a predictor of overall mortality (p 0.76).
In multivariable analysis, LVESD was independently
redictive of mortality after diagnosis (adjusted HR: 1.86,
5% CI: 1.24 to 2.80 for LVESD 40 mm vs. LVESD
40 mm, and adjusted HR: 1.04, 95% CI: 1.02 to 1.07 per
-mm LVESD increment) (Table 2). Patients with
VESD 22 mm/m2 had poorer survival with medical and
Figure 3 Survival Free of Cardiac Death According
to LVESD in Patients With Organic MR
Survival free of cardiac death according to LVESD in patients with organic MR:
(A) conservative management (B) medical and surgical treatment. Abbrevia-
tions as in Figure 1.
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LV Size in Mitral Regurgitation November 17, 2009:1961–8urgical management (adjusted HR: 1.73, 95% CI: 1.14 to
.60, p  0.003).
The relationship between LVESD 40 mm and mortal-
ty was still significant after excluding patients with mod-
rate MR (p  0.003) or patients with history of infective
ndocarditis (p  0.02).
During follow-up, cardiac mortality was recorded in 103
ases. Cardiac mortality rates for 1, 5, and 10 years were
 0.5%, 10  1%, and 21  2%, respectively, for the
ntire cohort. The 10-year cardiac mortality was signifi-
antly lower for patients with LVESD 40 mm (Fig. 3B).
n multivariable analysis, LVESD as continuous and cate-
orical variable was independently predictive of cardiac
eath (Table 2).
Of the 552 patients in whom mitral valve surgery was
erformed, 88 died during post-operative follow-up (5.2 
.4 years). In multivariable analysis, LVESD was an inde-
endent predictor of post-operative overall death and death
rom cardiac causes (Fig. 4, Table 2).
Cox proportional hazards analysis with surgery as a
ime-dependent variable showed that surgery was associ-
ted with reduced subsequent mortality (adjusted HR:
.62, 95% CI: 0.45 to 0.86, p  0.0035). There was no
ignificant interaction between LVESD 40 mm and the
agnitude of survival benefit after surgery (p  0.20),
hich was observed in patients with LVESD 40 mm
adjusted HR: 0.42, 95% CI: 0.24 to 0.73, p  0.002)
nd with LVESD 40 mm (adjusted HR: 0.65, 95% CI:
.44 to 0.96, p  0.028).
iscussion
his study is the first report of the relationship between
VESD and survival from diagnosis under medical man-
gement and after mitral surgery in MR due to flail leaflets.
Figure 4 Adjusted Post-Operative Overall Survival According
to LVESD in Operated Patients With Organic MR
Adjusted post-operative overall survival according to LVESD in
operated patients with organic MR. Abbreviations as in Figure 1.eur results show that LVESD is independently predictive
f survival in patients with organic MR under conservative
anagement in routine clinical practice. The effect of
VESD was powerful because after adjustment for age, sex,
omorbidity, symptoms, AF, and EF, each 1-mm LVESD
ncrement was associated with impressive 7% increase in
verall mortality and 13% increase in cardiac mortality.
hus, LVESD40 mm (22 mm/m2) was associated with
pproximately doubling of the risk of overall mortality and
ripling of the risk of cardiac death under medical manage-
ent, irrespective of characteristics that are now considered
lass I indications for surgery (symptoms, EF 60%).
oreover, our results show that LVESD 40 mm (22
m/m2) is not just predictive of excess mortality under
edical management with mortality increasing linearly
bove the cut-off of 40 mm, but also is an independent
eterminant of lower survival after surgical correction of
R despite the fact that surgery was associated with
arked mortality reduction. Thus, whereas surgery is re-
uired in patients with LVESD 40 mm, it is preferable to
ndicate mitral surgery before this threshold is reached to
void the excess post-operative mortality associated with
VESD 40 mm.
The management of MR is disputed. The general agree-
ent is that patients with overt symptoms should undergo
rompt mitral surgery (7,8) because of their high risk under
edical management (3). Symptomatic patients incur ex-
ess mortality after surgery (9,14). The other general con-
ensus (7,8) is that asymptomatic patients with severe
rganic MR and overt LV dysfunction should be considered
or mitral surgery. Consequently, in routine practice, simple
nd reproducible echocardiographic parameters of LV sys-
olic function with definite prognostic value are useful to
iscuss the best timing for mitral surgery. Interpretation of
ystolic function parameters in MR is complex (7,14,24). It
s widely agreed that LV dysfunction may be concealed
ehind a normal EF because the loading conditions are
rofoundly modified (18). Over time, patients with severe
hronic MR develop an irreversible impairment in LV
ystolic function and reduced EF is a sign of overt LV
ysfunction. With reduced EF, it has been observed that
ortality under medical management (3) and post-operative
ccurrence of LV dysfunction, congestive heart failure, and
eath are all increased in patients with organic MR (12–15).
nd-systolic LV characteristics are considered less pre-
oad-dependent (7,19) than EF. Data on the prognostic
mportance of LVESD are scarce (7), generally limited to
mall surgical studies without data on mortality (15–18).
hese reports indicated that LVESD was associated with
re-operative (18) or post-operative LV function (15,17,19).
owever, all these surgical series remained small or mingled
rganic and functional MR (15). Only a small cohort of
atients with severe MR suggested that LVESD was
ssociated with progression of symptoms or LV dysfunction
uring conservative follow-up (20). The guidelines of 1998
ndorsed a threshold of LVESD45 mm for surgery based
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November 17, 2009:1961–8 LV Size in Mitral Regurgitationn a series of 61 patients (19). However, this study group
ith rheumatic MR was extremely young and experienced
ew post-operative events (19) so that applicability of the
5-mm threshold is questionable in older patients with
egenerative MR (17,18,20). U.S. guidelines recently en-
orsed a surgical threshold of LVESD40 mm (7) whereas
uropean guidelines maintain a threshold of 45 mm (8).
Currently, mitral valve repair is the preferred surgical
rocedure for MR. This approach is supported by its low
isk and excellent long-term results of the procedure, but it
equires the precise identification of subgroups of patients at
igh risk under conservative management. The population
ncluded in the current study has a homogenous diagnosis of
ail leaflet. Although the presence of a flail leaflet might not
e systematically associated with severe MR (21), the
entricular dilation observed in this study is consistent with
hat observed in previous surgical series and denotes marked
olume overload. The relative risk of mortality under
edical management increased linearly with LVESD above
he cut-off of 40 mm. Consistent with previous studies,
itral surgery was associated with a significant reduction in
he risk of death. However, among operated patients,
VESD 40 mm remained independently predictive of
dverse outcome. The judgment on severe MR was rela-
ively uniform (95% of patients). There was no interaction
etween MR severity and outcome prediction of LVESD (p
or interaction  0.49). Despite the size of this series, we
annot assume that each possible subgroup (i.e., subgroup
ith moderate MR) follows the same rules.
Although in this study there was no interaction between
ex and LVESD 40 mm for predicting survival (p 
.21), recent data show that among patients with severe
rganic MR, women have higher mortality and lower
urgery rates than men (25). This is probably due to the fact
hat patients with small body size are allowed to develop
reater relative chamber dilation. Our data show that a
VESD 22 mm/m2 is associated with excess mortality.
his threshold can be used, particularly when discussing
urgery for severe organic MR in patients with small body
ize.
tudy strengths and limitations. A limitation of the
resent study was that whereas echocardiographic data were
rospectively collected, clinical and nonechocardiographic
ata were obtained by review of medical records. In multi-
ariable analysis, the center in which patients were enrolled
id not affect survival (p 0.16) whereas LVESD remained
redictive of outcome. There was no interaction between
he origin of patients (Europe vs. U.S.) and LVESD 40
m for predicting survival after diagnosis (p  0.14).
mong included cases, there were patients who presented
ith characteristics now known as “class I surgical indica-
ions by guidelines.” Surgery was delayed because physicians
udged that patients were well initially with medical man-
gement. Stratification by class I characteristics does not
ffect the results of our study and shows that LVESD
emains independently predictive of survival. This studyand the MIDA database) used “flail leaflet” as a surrogate
or severe MR. Although prominent flail usually is associ-
ted with severe MR, not all flail leaflets are associated with
evere MR, and not all patients in this study were felt, at the
ime of echocardiography interpretation, to have severe MR.
owever, we believe that these findings can be extrapolated
o most patients with chronic severe MR. We acknowledge
hat during the last 2 decades 2-dimensional transthoracic
chocardiographic imaging has undergone substantial evo-
ution allowing more accurate detection of flail leaflets. The
nclusion period (1980 to 1991 vs. 1992 to 2004) had no
nfluence on the prognostic impact of LVESD on outcome
p for interaction  0.29). There was no change in
easured LVESD over the years of the study (R2  0.03,
 0.69).
linical Implications
ur multicenter study demonstrates that LVESD is a
owerful predictor of survival in patients with pure organic
R due to flail leaflets. Therefore, it is essential to measure
V diameters in all patients with MR and to use LVESD
or clinical decision making. Patients with LVESD 40
m (22 mm/m2) do not have a benign outcome, exhibit
ncreased risk of death under conservative management, and
hould be promptly considered for mitral surgery, because
urgery considerably reduces mortality. The pejorative effect
f LVESD 40 mm (22 mm/m2) is also observed after
he surgical correction of MR. Therefore, in our opinion, in
atients with severe MR due to flail leaflets valve surgery
hould be considered, even in the absence of symptoms,
efore the end-systolic diameter exceeds 40 mm. Con-
ersely, patients with smaller end-systolic dimensions and
o symptoms incur low mortality risk under medical man-
gement and may be initially followed medically if there are
o other markers of high risk. In this context, serial LVESD
easurements represent an objective, valuable, and easily
easurable tool for discussing the optimal timing for
urgery.
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